# Study of ESG401 in Adults With Solid Tumors

> **NCT04892342** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shanghai Escugen Biotechnology Co., Ltd** · enrollment: 156 (actual)

## Conditions studied

- Neoplasms, Breast
- Neoplasms, Lung
- Neoplasms,Colorectal
- Neoplasms, Bladder
- Neoplasm of Stomach
- Neoplasms,Ovarian

## Interventions

- **DRUG:** ESG401

## Key facts

- **NCT ID:** NCT04892342
- **Lead sponsor:** Shanghai Escugen Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-14
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04892342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04892342, "Study of ESG401 in Adults With Solid Tumors". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04892342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*